News · 26 weeks78-61%
2026-01-182026-07-12
Mix4390d
- Insider24(56%)
- Other9(21%)
- SEC Filings7(16%)
- Offering1(2%)
- Analyst1(2%)
- Earnings1(2%)
Latest news
25 items- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 550 shares at a strike of $2.39 and sold $95,622 worth of shares (4,172 units at $22.92) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- PRCastle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ TestApproval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitisFRIENDSWOOD, Texas, July 14, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD)."We are proud to announce the final approval
- PRCastle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026FRIENDSWOOD, Texas, July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2026, after the close of market on Thursday, July 30, 2026.Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.Webcast DetailsThe live webcast can be accessed here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=gbu0MZxe, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/. Please access the web
- INSIDERChief Operating Officer Oelschlager Kristen M sold $209,650 worth of shares (8,586 units at $24.42) as part of a pre-agreed trading plan, decreasing direct ownership by 28% to 21,874 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J sold $238,916 worth of shares (9,836 units at $24.29) as part of a pre-agreed trading plan and exercised 6,214 shares at a strike of $2.39 (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- SECSEC Form 144 filed by Castle Biosciences Inc.144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
- PRDecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node BiopsyNewly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogramPatients classified as low risk by the i31-SLNB result had a 2.6% observed SLN positivity rate, falling well below the National Comprehensive Cancer Network (NCCN) 5% threshold used to consider avoiding sentinel lymph node biopsy (SLNB), compared with a 5.8% observed positivity rate for the MIA nomogramFRIENDSWOOD, Texas, June 25, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient car
- ANALYSTRoth Capital initiated coverage on Castle Biosciences with a new price targetRoth Capital initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $40.00
- PRCastle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business JournalStokes was one of 22 financial leaders recognized in the Greater Houston areaFRIENDSWOOD, Texas, June 23, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that Frank Stokes, its chief financial officer, has been named a 2026 CFO Awards honoree by the Houston Business Journal. Stokes is among 22 chief financial officers from across the Greater Houston area recognized for their financial leadership and contributions to their organizations' success. Honorees will be celebrated a
- PRCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 15, 2026, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 172 employees covering an aggregate of 204,925 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting commence
- INSIDERChief Operating Officer Oelschlager Kristen M sold $177,837 worth of shares (8,587 units at $20.71) as part of a pre-agreed trading plan, decreasing direct ownership by 22% to 30,460 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 550 shares at a strike of $2.39 and sold $86,194 worth of shares (4,172 units at $20.66) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- SECSEC Form 144 filed by Castle Biosciences Inc.144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
- PRCastle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's EsophagusFRIENDSWOOD, Texas, June 16, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its TissueCypher® Barrett's Esophagus Test has surpassed 100,000 clinical test orders. TissueCypher is an AI-derived precision medicine test designed to predict a patient's five-year risk of progression from Barrett's esophagus (BE) to high-grade dysplasia or esophageal adenocarcinoma."Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), a gastrointestinal cancer associated with poor survival outcomes," said Emmanuel Gorospe, M.D., MPH, FACG, FASGE, board-certified gastr
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 6,214 shares at a strike of $2.39 and sold $205,149 worth of shares (9,836 units at $20.86) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- SECSEC Form 144 filed by Castle Biosciences Inc.144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
- INSIDERSEC Form 4 filed by Director Olson Tiffany4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Goldberg Ellen4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Harrison Miles4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Cotton Rodney4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Caple Kim4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Bradbury Daniel4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERSEC Form 4 filed by Director Cole G Bradley4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- SECCastle Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)
- INSIDERDirector Cole G Bradley converted options into 13,667 shares, increasing direct ownership by 71% to 32,976 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
CSTL FAQ
7 questionsWhat does Castle Biosciences Inc. do?
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test...Where does CSTL stock trade?
Castle Biosciences Inc. (CSTL) is listed on NASDAQ.What sector and industry is CSTL in?
Castle Biosciences Inc. operates in the Health Care sector, Medical Specialities industry.When did Castle Biosciences Inc. go public?
Castle Biosciences Inc. (CSTL) completed its IPO in 2019.What are analysts saying about CSTL?
Castle Biosciences Inc. has had 6 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $4000.00 price target on 2026-06-25. Recent price targets range from $2500.00 to $4000.00.What companies are similar to CSTL?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare CSTL side-by-side with any of them on Quantisnow.How can I track CSTL on Quantisnow?
Quantisnow aggregates Castle Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CSTL to receive live email and push alerts on every new disclosure.